Skip Navigation
  Print Page

Staff Detail

Skip sharing on social media links
Share this:

Kapogiannis, Bill G

Formal Title:

Medical Officer

Responsibilities:

Program Director, Adolescent Medicine Trials Network for HIV/AIDS Interventions

Phone:

301-402-0698

Email:

wk78s@nih.gov

Address:

6100 EXECUTIVE BLVD Room 4B11J, MSC 7510
Bethesda Md 20892-7510
For FedEx use:
Rockville Md 20852

Biosketch:

Bill G. Kapogiannis, M.D., is a board-certified infectious disease specialist in pediatrics and internal medicine. He received his M.D. from the University of Illinois at Chicago, College of Medicine, and completed a four year Internal Medicine/Pediatrics Residency Program at the University of Illinois at Chicago before finishing a combined fellowship training in Infectious Diseases within the departments of Internal Medicine and Pediatrics at Emory University, Atlanta, Georgia. Part of Dr. Kapogiannis' research involved assembling, collecting, and analyzing immunologic data on an HIV-positive adolescent cohort in Atlanta. Dr. Kapogiannis is the Scientific Director of the Adolescent Trials Network for HIV/AIDS Interventions, which is evaluating interventions for treatment and management of HIV infection and its complications among youth, as well as the prevention of HIV transmission in the adolescent population, including HIV vaccine and microbicide studies.

Publications (PubMed):

 
Title Authors Publication Date
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Rudy BJ,Kapogiannis BG,Lally MA,Gray GE,Bekker LG,Krogstad P,McGowan IJ Acquir Immune Defic Syndr2010 Jul
Introduction: Paving the way for biomedical HIV prevention interventions in youth.Kapogiannis BG,Handelsman E,Ruiz MS,Lee SJ Acquir Immune Defic Syndr2010 Jul
Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).Kapogiannis BG,Soe MM,Nesheim SR,Abrams EJ,Carter RJ,Farley J,Palumbo P,Koenig LJ,Bulterys MClin Infect Dis2011 Nov
Rolling up our sleeves now to reap the benefits later: preparing the community for an adolescent HIV vaccine.Kapogiannis BG,Lee SSCurr Opin HIV AIDS2007 Sep
Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults at Risk for HIV Infection: Is an Ounce of Prevention Worth a Pound of Cure?Pace JE,Siberry GK,Hazra R,Kapogiannis BGClin Infect Dis2012 Dec 7
The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.Hosek SG,Siberry G,Bell M,Lally M,Kapogiannis B,Green K,Fernandez MI,Rutledge B,Martinez J,Garofalo R,Wilson CM,Adolescent Trials Network for HIVAIDS Interventions (ATN)J Acquir Immune Defic Syndr2013 Apr 1
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology